Long-term effects on bone mineral density after four years of treatment with two intensive combination strategies, including initially high-dose prednisolone, in early rheumatoid arthritis patients: the COBRA-light trial.
M J J LucassenMarieke M Ter WeeD den UylN P C KonijnMichael T NurmohamedAlexandre E VoskuylDirkjan van SchaardenburgP J S M KerstensIrene E M BultinkMaarten BoersWillem F LemsPublished in: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2021)
In a treat-to-target design in early RA, over 4 years, no differences between groups were found in change in BMD at total hip, femoral neck and the lumbar spine. At the hip, bone loss was around 3% in both groups, while mild bone loss was observed at lumbar spine, both in patients starting prednisolone 60 and 30 mg/day. These data suggest that the well-known negative effects of prednisolone can be modulated by modern treatment of RA.
Keyphrases
- bone loss
- bone mineral density
- rheumatoid arthritis patients
- high dose
- total hip
- disease activity
- rheumatoid arthritis
- postmenopausal women
- end stage renal disease
- body composition
- clinical trial
- low dose
- randomized controlled trial
- systemic lupus erythematosus
- study protocol
- prognostic factors
- ankylosing spondylitis
- electronic health record
- stem cell transplantation
- machine learning
- artificial intelligence
- combination therapy
- systemic sclerosis
- data analysis